Beth Seidenberg’s Post

Today we are excited to emerge from stealth with a $135 million Series A financing. Westlake Village BioPartners® incubated the company and led the Series A financing, with 5AM Ventures and Foresite Capital as co-leads and with participation from Corner Ventures. Latigo is focused on developing non-opioid novel pain medicines against genetically validated targets. Read the full press release here: https://lnkd.in/g6BS44pT #biotech #genetics #opioid

Today, Boehringer Ingelheim and 3T Biosciences are pleased to announce a second partnership focused on discovering and developing next-generation #cancer #immunotherapies.    This new collaboration It brings together 3T’s best-in-class 3T-TRACE discovery platform with Boehringer Ingelheim’s commitment to develop first-in-class immuno-oncology treatments that boost the immune system’s ability to recognize, attack and kill tumors.   Read more about this collaboration in our press release: https://lnkd.in/griNxiqm

Congratulations to Westlake-backed Kyverna Therapeutics for achieving this important milestone that offers hope to patients suffering from #multiplesclerosis!

Congratulations to Westlake Village BioPartners®-backed Kyverna Therapeutics for receiving FDA Clearance of their IND for KYV-101, a novel fully human CD19 CAR T-cell therapy for the treatment of scleroderma!

We are thrilled to share the appointment of Shephard Mpofu as our Senior Vice President of Development to lead clinical development and translational sciences. We look forward to adding his experience having previously led the development of secukinumab to our Senior Leadership Team as we advance transformative medicines for patients. Read more about Dr. Mpofu's impressive career in drug development here: https://lnkd.in/gJKdv2Q5

We’re thrilled to announce the launch of our third fund of $450 million to incubate and grow early stage next-generation #biotechnology companies in the #LosAngeles region and beyond.   The new fund will be managed by founding managing director Beth Seidenberg, M.D., and managing directors Mira Chaurushiya, Ph.D., and David Allison, Ph.D.   Read more: https://lnkd.in/gRY4YYJW   #venturecapital #biotechinvesting

We are excited to announce as an #AADLateBreaker data from Part A of our Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa. Read more here: https://lnkd.in/gq6P2yiW #AAD2023

https://lnkd.in/gGdVcdM

https://lnkd.in/gjKmFxX #biotechnologies #venturecapital